Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial

Uwe Reuter, Annelies Van Dycke, Jan Versijpt, Dagny Holle-Lee, Mark Kristof Farkas, Stewart J Tepper, Giovanna Forero, Lei Luo, Hua Guo, Eric Cohen, Brett Dabruzzo, Pranav Gandhi, Krisztian Nagy

Open source

DOI
10.1016/s1474-4422(26)00214-0
Published
2026-09
Container
The Lancet Neurology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-26-00214-0,
  title = {Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial},
  author = {Uwe Reuter and Annelies Van Dycke and Jan Versijpt and Dagny Holle-Lee and Mark Kristof Farkas and Stewart J Tepper and Giovanna Forero and Lei Luo and Hua Guo and Eric Cohen and Brett Dabruzzo and Pranav Gandhi and Krisztian Nagy},
  year = {2026},
  journal = {The Lancet Neurology},
  doi = {10.1016/s1474-4422(26)00214-0},
  url = {https://doi.org/10.1016/s1474-4422(26)00214-0}
}

RIS

TY  - JOUR
TI  - Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial
AU  - Uwe Reuter
AU  - Annelies Van Dycke
AU  - Jan Versijpt
AU  - Dagny Holle-Lee
AU  - Mark Kristof Farkas
AU  - Stewart J Tepper
AU  - Giovanna Forero
AU  - Lei Luo
AU  - Hua Guo
AU  - Eric Cohen
AU  - Brett Dabruzzo
AU  - Pranav Gandhi
AU  - Krisztian Nagy
PY  - 2026
JO  - The Lancet Neurology
DO  - 10.1016/s1474-4422(26)00214-0
UR  - https://doi.org/10.1016/s1474-4422(26)00214-0
ER  - 

APA

Reuter, U., Dycke, A. V., Versijpt, J., Holle-Lee, D., Farkas, M. K., Tepper, S. J., Forero, G., Luo, L., Guo, H., Cohen, E., Dabruzzo, B., Gandhi, P., & Nagy, K. (2026). Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(26)00214-0

Source records